A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma. Publication

cited authors

  • Odia, Yazmin; Goldlust, Samuel Aaron; Mehta, Minesh P; Lassman, Andrew B; Colman, Howard; Kumthekar, Priya; Mason, Warren P; Harrison, Rebecca A; Butowski, Nicholas A; Venur, Vyshak; Plotkin, Scott Randall; Schulder, Michael; Boockvar, John A; Duic, J Paul; Li, Kai; Liu, Yang; Tamir, Sharon; Mundy, Gregory; Shacham, Sharon; Wen, Patrick Y

fiu authors

publication date

  • May 20, 2021

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

volume

  • 39

issue

  • 15